SCHEMBL3603459

SCHEMBL3603459

C=Cc1c(C)nn(C)c1Oc1cc(O[C@@H](C)C(=O)N(C)C)c(Cl)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.38
CYP2C19 P33261 3/20 0.38
CYP1A2 P05177 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.36
GPBAR1 Q8TDU6 7/20 0.36
GLA P06280 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
HPGD P15428 1/20 0.32
ALOX12 P18054 1/20 0.32
MAPT P10636 3/20 0.31
HTT P42858 2/20 0.31
LMNA P02545 2/20 0.31
KDM4E B2RXH2 1/20 0.31
RECQL P46063 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
NR2F2 P24468 1/20 0.31
ESR1 P03372 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3605072 0.90 KDM4E (0.39) CYP2C9CYP2C19CYP1A2SMN1; SMN2GPBAR1
SCHEMBL3608916 0.90 KDM4E (0.39) CYP2C9CYP2C19CYP1A2SMN1; SMN2GPBAR1
SCHEMBL3603940 0.90 KDM4E (0.39) CYP2C9CYP2C19CYP1A2SMN1; SMN2GPBAR1
SCHEMBL3610418 0.89 SMN1; SMN2 (0.37) CYP2C9CYP2C19CYP1A2SMN1; SMN2GPBAR1
SCHEMBL3606304 0.88 PPOX (0.40) CYP2C9CYP2C19CYP1A2SMN1; SMN2GPBAR1
SCHEMBL3607949 0.84 SMN1; SMN2 (0.35) CYP2C9CYP2C19CYP1A2SMN1; SMN2GPBAR1
SCHEMBL3617128 0.84 SMN1; SMN2 (0.38) CYP2C9CYP2C19CYP1A2SMN1; SMN2GPBAR1
SCHEMBL3607366 0.83 SMN1; SMN2 (0.35) CYP2C9CYP2C19CYP1A2SMN1; SMN2GPBAR1
SCHEMBL3605551 0.83 SMN1; SMN2 (0.39) CYP2C9CYP2C19CYP1A2SMN1; SMN2GPBAR1
SCHEMBL3609773 0.82 SMN1; SMN2 (0.35) CYP2C9CYP2C19CYP1A2SMN1; SMN2GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R CYP2C9 145/4885CYP2C19 79/4885CYP1A2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.